<DOC>
	<DOCNO>NCT01327664</DOCNO>
	<brief_summary>This study provide patient complete AIN457 Phase II Phase III clinical trial non-infectious uveitis continued access treatment AIN457 collect safety data information long term clinical use treatment AIN457 .</brief_summary>
	<brief_title>Study Evaluate Long Term Use Treatment With AIN457 Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients must able understand communicate investigator comply requirement study must give write , sign , date informed consent study assessment perform Patient currently enrol CAIN457A2208 complete core extension study treatment period ongoing AIN457 phase III clinical trial Studies ( e.g. , CAIN457C2301 CAIN457C2301E1 ) Willingness discontinue AIN457 wean standard care immunosuppressive therapy recommend study investigator Need treatment ocular procedure systemic medication prohibit study include alkylating agent another biologic therapy AIN457 Pregnant nursing ( lactate ) woman Women childbearing potential unwilling use protocol define acceptable method contraception throughout study 16 week study drug discontinuation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Quiescent uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>